Area of research
Pulmonary and Respiratory Medicine · Oncology
Research interest
Research focused on Atezolizumab and Hazard ratio, with related work in Attention deficit hyperactivity disorder, Bevacizumab, Pharmacokinetics. Notable publications include 'Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study', 'Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)', and 'Applications of Model-Based Meta-Analysis in Drug Development'.
Utilizing Minimal Physiologically Based Pharmacokinetic Modeling to Bridge Bevacizumab Pharmacokinetics from Adult to Pediatric Patients
International Consensus on Standard Outcome Measures for Neurodevelopmental Disorders
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors
Early Decision Making in a Randomized Phase <scp>II</scp> Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition‐Survival Modeling Framework
Applications of Model-Based Meta-Analysis in Drug Development
Tumor Growth Inhibition-Overall Survival (TGI-OS) Model for Subgroup Analysis Based on Post-Randomization Factors: Application for Anti-drug Antibody (ADA) Subgroup Analysis of Atezolizumab in the IMpower150 Study
Evaluation of atezolizumab immunogenicity: Clinical pharmacology (part 1)
Population Pharmacokinetics, Efficacy Exposure-response Analysis, and Model-based Meta-analysis of Fenebrutinib in Subjects with Rheumatoid Arthritis
Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study
Prenatal antidepressant exposure and the risk of attention-deficit hyperactivity disorder in children: A systematic review and meta-analysis